Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2024-05-07 Capital/Financing Update
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
ASTRAZENECA COMPLETES CELLECTIS EQUITY INVESTMENT
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It announces the completion of an equity investment in Cellectis, including financial details of the investment and collaboration agreement. The document is an announcement of a capital investment transaction rather than a full financial report or earnings release. It does not contain comprehensive financial statements or detailed management discussion. The nature of the content fits best under Capital/Financing Update (CAP) as it relates to company fundraising and equity investment activities.
2024-05-07 English
AstraZeneca completes Cellectis equity investment
Share Issue/Capital Change Classification · 99% confidence The document begins with 'RNS Number : 2725N' and is dated '07 May 2024'. It announces a specific corporate action: 'AstraZeneca completes equity investment agreement with Cellectis'. The structure, including the RNS header, the announcement of a specific event (an investment completion), and the concluding boilerplate text referencing RNS and the London Stock Exchange, strongly indicates this is a regulatory news service announcement. Since it details a specific corporate transaction (equity investment/financing aspect) but is presented as a brief news item via RNS, it fits best under the general Regulatory Filings category (RNS) or potentially Capital/Financing Update (CAP). However, the presence of the RNS identifier and the format strongly suggest RNS is the primary classification for this type of immediate regulatory disclosure that isn't a full report (like 10-K or IR). Given the options, RNS is the most appropriate catch-all for this format of regulatory news release.
2024-05-07 English
CALQUENCE COMBINATION IMPROVED PFS IN 1L MCL
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains a detailed announcement about clinical trial results for Calquence in mantle cell lymphoma, including trial design, endpoints, and company commentary. The document is not an annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing used by foreign companies to report material information to the SEC. The document is over 11,000 characters and contains substantive information but is not a financial report or presentation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2024-05-02 English
Calquence combination improved PFS in 1L MCL
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' (9163M) and is dated May 2, 2024. It contains a headline announcing positive clinical trial results for AstraZeneca's drug Calquence in treating mantle cell lymphoma. The text includes quotes from company executives and investigators, details about the ECHO Phase III trial, and standard boilerplate information about AstraZeneca and RNS distribution. This format—a brief, timely announcement of significant corporate or clinical news distributed via the Regulatory News Service (RNS) of the London Stock Exchange—is characteristic of a general regulatory announcement, rather than a comprehensive financial report (like 10-K or IR) or a specific shareholder communication (like DEF 14A). Since it is a general regulatory announcement that doesn't fit the more specific categories (like DIV, DIRS, or ER), the most appropriate classification is the general regulatory filing category.
2024-05-02 English
TOTAL VOTING RIGHTS
Major Shareholding Notification Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, reporting total voting rights as of 30 April 2024. It references the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1 and provides the total number of voting rights for shareholders' notification purposes. The document is short (3158 characters) and primarily serves as a notification of voting rights rather than a detailed report or financial statement. It does not contain financial results, management discussion, or other report content. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes or status of significant share ownership or voting rights.
2024-05-01 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short notification released via RNS (London Stock Exchange news service). It explicitly states the RNS Number and provides an update on the total number of voting rights and issued share capital as of a specific date (April 30, 2024). This type of regulatory disclosure regarding capital structure changes or voting rights is a standard regulatory announcement. While it relates to capital, it is not a formal financing document (CAP) or a share issue announcement (SHA), but rather a mandatory disclosure under the Disclosure and Transparency Rule 5.6.1. Given the source (RNS) and the nature of the content (voting rights denominator update), it fits best under the general Regulatory Filings category (RNS) or potentially Declaration of Voting Results & Voting Rights Announcements (DVA). Since DVA is specifically for *results* of votes, and this is a general capital/voting rights disclosure, RNS is the most appropriate general regulatory filing code for this specific type of mandatory update.
2024-05-01 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.